Please provide your email address to receive an email when new articles are posted on . In a randomized double blind, placebo-controlled trial with older men assigned either AndroGel 1% (transdermal ...

May 7, 2009 — The US Food and Drug Administration (FDA) held a press conference today to announce a change in the labeling of the testosterone gel products AndroGel 1% (Solvay Pharmaceuticals) and ...

YONKERS, N.Y., May 20 (UPI) -- Investigators at Consumer Reports say the directions for testosterone gel say the gel is flammable until dry and avoid smoking or an open flame until dry. Consumer ...

Upsher-Smith Laboratories announced it has received final approval from the FDA for its New Drug Application (NDA) for Vogelxo (testosterone) gel for topical use. Vogelxo is a Schedule CIII androgen ...

Compared with exercise alone, combining exercise training with testosterone gel application did not result in longer 6-minute walk distances (6MWDs) in older women with a recent hip fracture repair ...

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug ...

Perrigo announced that it has received approval from the FDA for its New Drug Application (NDA) for Testosterone Gel 1%, the generic version of AbbVie’s AndroGel 1%. AndroGel, a Schedule III ...

Active ingredient: Testosterone 10 mg/0.5 g actuation; metered-dose pump; topical gel. Indication: Primary hypogonadism. Hypogonadotropic hypogonadism. Pharmacology: Fortesta is a topical gel ...

San Francisco, Calif. and Torrance, Calif. (June 20, 2002) – A Phase 3 study conducted at multiple research centers in the U.S. under the direction of Ronald Swerdloff, MD, Principal Investigator at ...

A case that first appeared in a medical journal several years ago has recently resurfaced in the media, highlighting an unexpected risk of hormone therapies: a baby girl in Sweden developed unusually ...

LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. BPAX reports a New Drug Application (NDA) has been accepted for filing by the U.S.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...